Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

CHEMTUBIO, a new ERC project at IBEC to study enzymes with therapeutic potential

by IBEC - Institut de Bioenginyeria de Catalunya

10 months ago
CHEMTUBIO, tubulin

The project will study the chemistry of enzymes that erase microtubule modifications. These enzymes are essential for the functioning of our cells and have shown great promise as potential therapeutic...

WLCC2025: An innovative targeted therapy shows promising results in the treatment of lung cancer with ROS1 gene alterations

by VHIO

10 months ago
ROS1 gene, non-small cell lung cancer (NSCLC), zidesamtinib

Results from the international Phase 1/2 clinical trial ARROS-1 show promising outcomes with zidesamtinib, a novel ROS1 selective inhibitor under investigation, in patients with advanced non-small cel...

Pharmacokinetics and Pharmacodynamics (PK/PD) Studies in Drug Development: From ADME Principles to Translational Applications

by AMSbiopharma

10 months ago
Pharmacokinetics and Pharmacodynamics (PK/PD)

Pharmacokinetics describes the journey of a drug through de body, covering absorption, distribution, metabolism, and excretion (ADME). This trajectory determines the concentration of the drug in the b...

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

by Ysios Capital

10 months ago
Lorundrostat, Hypertension, Launch-HTN, Mineralys Therapeutics

Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment

by Ysios Capital

10 months ago
coagulation, VarmX partners, CSL, VMX-C001, anticoagulants targeting activated factor Xa (FXa DOACs)

Financiación completa del ensayo de fase III del VMX-C001, desarrollo del producto en fase avanzada, fabricación y actividades previas al lanzamiento.

Highlight Therapeutics closes a €15 million funding round led by Buenavista

by Highlight Therapeutics

10 months ago
Highlight Therapeutics, Columbus Venture Partners, Buenavista Equity Partners

Highlight Therapeutics is a Spanish biotechnology company specialising in immuno-oncology, focused on the development of innovative cancer therapies. Its lead investigational compound, BO-112, is a do...

ARTHEx Biotech Upsizes Series B Financing Round to $87 millones

by ARTHEx Biotech

10 months ago
ATX-01, Myotonic Dystrophy Type 1 (DM1), ArthemiRTM, MBNL protein, toxic DMPK mRNA, microRNA23b (miR-23b), ARTHEx Biotech

Proceeds to support further clinical development of lead program ATX-01 in Myotonic Dystrophy Type1, a unique therapy currently in Phase I-IIa, targeting miR23b

Parc Taulí will evaluate a new therapy for Angelman syndrome

by Instituto de Investigación e Innovación Parc Taulí

9 months ago
Angelman syndrome, antisense oligonucleotide (ASO), gene UBE3A

The center is participating in an international clinical trial that seeks to improve patients' quality of life by addressing sleep, communication and motor disorders.

The VHIR and the Prous Institute will promote high-impact research projects in early stages of development

by Vall d’Hebron

The aim of this strategic agreement is to promote initiatives with significant biomedical potential which, despite their innovative value, lack sufficient financial resources in their early stages of ...

ORYZON to sponsor first Phelan-McDermid syndrome (PMS) burden of illness study

by Oryzon Genomics

9 months ago
Phelan-McDermid syndrome (PMS), LSD1 inhibitors, Vafidemstat, SHANK3 gene

Oryzon Genomics is proud to announce its participation as a sponsor of the first-ever Phelan-McDermid syndrome (PMS) burden of illness study. The study is led by CureShank, a research advocacy organiz...

Elevating Clinical Development with Specialized Medical Services

by Pivotal

9 months ago
Clinical Development, Medical Solutions

In the complex world of pharmaceutical and biotechnology drug development, PIVOTAL serves as your trusted medical partner – delivering expert medical oversight and strategic insight across every pha...

Expertos exponen los cambios sanitarios, políticos y sociales necesarios para aprovechar al máximo los avances en el tratamiento del Alzheimer

by Hospital de la Santa Creu i Sant Pau

9 months ago
lecanemab, donanemab

La aprobación de nuevos medicamentos con anticuerpos para la enfermedad de Alzheimer –lecanemab y donanemab– y de pruebas diagnósticas en sangre marcan el inicio de una nueva era en el diagnóst...